共查询到20条相似文献,搜索用时 78 毫秒
1.
Tatsuhiro Sato Akio Nakashima Lea Guo Fuyuhiko Tamanoi 《The Journal of biological chemistry》2009,284(19):12783-12791
Rheb G-protein plays critical roles in the TSC/Rheb/mTOR signaling pathway
by activating mTORC1. The activation of mTORC1 by Rheb can be faithfully
reproduced in vitro by using mTORC1 immunoprecipitated by the use of
anti-raptor antibody from mammalian cells starved for nutrients. The low
in vitro kinase activity against 4E-BP1 of this mTORC1 preparation is
dramatically increased by the addition of recombinant Rheb. On the other hand,
the addition of Rheb does not activate mTORC2 immunoprecipitated from
mammalian cells by the use of anti-rictor antibody. The activation of mTORC1
is specific to Rheb, because other G-proteins such as KRas, RalA/B, and Cdc42
did not activate mTORC1. Both Rheb1 and Rheb2 activate mTORC1. In addition,
the activation is dependent on the presence of bound GTP. We also find that
the effector domain of Rheb is required for the mTORC1 activation. FKBP38, a
recently proposed mediator of Rheb action, appears not to be involved in the
Rheb-dependent activation of mTORC1 in vitro, because the preparation
of mTORC1 that is devoid of FKBP38 is still activated by Rheb. The addition of
Rheb results in a significant increase of binding of the substrate protein
4E-BP1 to mTORC1. PRAS40, a TOR signaling (TOS) motif-containing protein that
competes with the binding of 4EBP1 to mTORC1, inhibits Rheb-induced activation
of mTORC1. A preparation of mTORC1 that is devoid of raptor is not activated
by Rheb. Rheb does not induce autophosphorylation of mTOR. These results
suggest that Rheb induces alteration in the binding of 4E-BP1 with mTORC1 to
regulate mTORC1 activation.Rheb defines a unique member of the Ras superfamily G-proteins
(1). We have shown that Rheb
proteins are conserved and are found from yeast to human
(2). Although yeast and fruit
fly have one Rheb, mouse and human have two Rheb proteins termed Rheb1 (or
simply Rheb) and Rheb2 (RhebL1)
(2). Structurally, these
proteins contain G1-G5 boxes, short stretches of amino acids that define the
function of the Ras superfamily G-proteins including guanine nucleotide
binding (1,
3,
4). Rheb proteins have a
conserved arginine at residue 15 that corresponds to residue 12 of Ras
(1). The effector domain
required for the binding with downstream effectors encompasses the G2 box and
its adjacent sequences (1,
5). Structural analysis by
x-ray crystallography further shows that the effector domain is exposed to
solvent, is located close to the phosphates of GTP especially at residues
35–38, and undergoes conformational change during GTP/GDP exchange
(6). In addition, all Rheb
proteins end with the CAAX (C is cysteine, A is an aliphatic amino
acid, and X is the C-terminal amino acid) motif that signals
farnesylation. In fact, we as well as others have shown that these proteins
are farnesylated
(7–9).Rheb plays critical roles in the TSC/Rheb/mTOR signaling, a signaling
pathway that plays central roles in regulating protein synthesis and growth in
response to nutrient, energy, and growth conditions
(10–14).
Rheb is down-regulated by a TSC1·TSC2 complex that acts as a
GTPase-activating protein for Rheb
(15–19).
Recent studies established that the GAP domain of TSC2 defines the functional
domain for the down-regulation of Rheb
(20). Mutations in the
Tsc1 or Tsc2 gene lead to tuberous sclerosis whose symptoms
include the appearance of benign tumors called hamartomas at different parts
of the body as well as neurological symptoms
(21,
22). Overexpression of Rheb
results in constitutive activation of mTOR even in the absence of nutrients
(15,
16). Two mTOR complexes,
mTORC1 and mTORC2, have been identified
(23,
24). Whereas mTORC1 is
involved in protein synthesis activation mediated by S6K and 4EBP1, mTORC2 is
involved in the phosphorylation of Akt in response to insulin. It has been
suggested that Rheb is involved in the activation of mTORC1 but not mTORC2
(25).Although Rheb is clearly involved in the activation of mTOR, the mechanism
of activation has not been established. We as well as others have suggested a
model that involves the interaction of Rheb with the TOR complex
(26–28).
Rheb activation of mTOR kinase activity using immunoprecipitated mTORC1 was
reported (29). Rheb has been
shown to interact with mTOR
(27,
30), and this may involve
direct interaction of Rheb with the kinase domain of mTOR
(27). However, this Rheb/mTOR
interaction is a weak interaction and is not dependent on the presence of GTP
bound to Rheb (27,
28). Recently, a different
model proposing that FKBP38 (FK506-binding protein
38) mediates the activation of
mTORC1 by Rheb was proposed
(31,
32). In this model, FKBP38
binds mTOR and negatively regulates mTOR activity, and this negative
regulation is blocked by the binding of Rheb to FKBP38. However, recent
reports dispute this idea
(33).To further characterize Rheb activation of mTOR, we have utilized an in
vitro system that reproduces activation of mTORC1 by the addition of
recombinant Rheb. We used mTORC1 immunoprecipitated from nutrient-starved
cells using anti-raptor antibody and have shown that its kinase activity
against 4E-BP1 is dramatically increased by the addition of recombinant Rheb.
Importantly, the activation of mTORC1 is specific to Rheb and is dependent on
the presence of bound GTP as well as an intact effector domain. FKBP38 is not
detected in our preparation and further investigation suggests that FKBP38 is
not an essential component for the activation of mTORC1 by Rheb. Our study
revealed that Rheb enhances the binding of a substrate 4E-BP1 with mTORC1
rather than increasing the kinase activity of mTOR. 相似文献
2.
3.
Ruben K. Dagda Salvatore J. Cherra III Scott M. Kulich Anurag Tandon David Park Charleen T. Chu 《The Journal of biological chemistry》2009,284(20):13843-13855
Mitochondrial dysregulation is strongly implicated in Parkinson disease.
Mutations in PTEN-induced kinase 1 (PINK1) are associated with familial
parkinsonism and neuropsychiatric disorders. Although overexpressed PINK1 is
neuroprotective, less is known about neuronal responses to loss of PINK1
function. We found that stable knockdown of PINK1 induced mitochondrial
fragmentation and autophagy in SH-SY5Y cells, which was reversed by the
reintroduction of an RNA interference (RNAi)-resistant plasmid for PINK1.
Moreover, stable or transient overexpression of wild-type PINK1 increased
mitochondrial interconnectivity and suppressed toxin-induced
autophagy/mitophagy. Mitochondrial oxidant production played an essential role
in triggering mitochondrial fragmentation and autophagy in PINK1 shRNA lines.
Autophagy/mitophagy served a protective role in limiting cell death, and
overexpressing Parkin further enhanced this protective mitophagic response.
The dominant negative Drp1 mutant inhibited both fission and mitophagy in
PINK1-deficient cells. Interestingly, RNAi knockdown of autophagy proteins
Atg7 and LC3/Atg8 also decreased mitochondrial fragmentation without affecting
oxidative stress, suggesting active involvement of autophagy in morphologic
remodeling of mitochondria for clearance. To summarize, loss of PINK1 function
elicits oxidative stress and mitochondrial turnover coordinated by the
autophagic and fission/fusion machineries. Furthermore, PINK1 and Parkin may
cooperate through different mechanisms to maintain mitochondrial
homeostasis.Parkinson disease is an age-related neurodegenerative disease that affects
∼1% of the population worldwide. The causes of sporadic cases are unknown,
although mitochondrial or oxidative toxins such as
1-methyl-4-phenylpyridinium, 6-hydroxydopamine
(6-OHDA),3 and
rotenone reproduce features of the disease in animal and cell culture models
(1). Abnormalities in
mitochondrial respiration and increased oxidative stress are observed in cells
and tissues from parkinsonian patients
(2,
3), which also exhibit
increased mitochondrial autophagy
(4). Furthermore, mutations in
parkinsonian genes affect oxidative stress response pathways and mitochondrial
homeostasis (5). Thus,
disruption of mitochondrial homeostasis represents a major factor implicated
in the pathogenesis of sporadic and inherited parkinsonian disorders (PD).The PARK6 locus involved in autosomal recessive and early-onset PD
encodes for PTEN-induced kinase 1 (PINK1)
(6,
7). PINK1 is a cytosolic and
mitochondrially localized 581-amino acid serine/threonine kinase that
possesses an N-terminal mitochondrial targeting sequence
(6,
8). The primary sequence also
includes a putative transmembrane domain important for orientation of the
PINK1 domain (8), a conserved
kinase domain homologous to calcium calmodulin kinases, and a C-terminal
domain that regulates autophosphorylation activity
(9,
10). Overexpression of
wild-type PINK1, but not its PD-associated mutants, protects against several
toxic insults in neuronal cells
(6,
11,
12). Mitochondrial targeting
is necessary for some (13) but
not all of the neuroprotective effects of PINK1
(14), implicating involvement
of cytoplasmic targets that modulate mitochondrial pathobiology
(8). PINK1 catalytic activity
is necessary for its neuroprotective role, because a kinase-deficient K219M
substitution in the ATP binding pocket of PINK1 abrogates its ability to
protect neurons (14). Although
PINK1 mutations do not seem to impair mitochondrial targeting, PD-associated
mutations differentially destabilize the protein, resulting in loss of
neuroprotective activities
(13,
15).Recent studies indicate that PINK1 and Parkin interact genetically
(3,
16-18)
to prevent oxidative stress
(19,
20) and regulate mitochondrial
morphology (21). Primary cells
derived from PINK1 mutant patients exhibit mitochondrial fragmentation with
disorganized cristae, recapitulated by RNA interference studies in HeLa cells
(3).Mitochondria are degraded by macroautophagy, a process involving
sequestration of cytoplasmic cargo into membranous autophagic vacuoles (AVs)
for delivery to lysosomes (22,
23). Interestingly,
mitochondrial fission accompanies autophagic neurodegeneration elicited by the
PD neurotoxin 6-OHDA (24,
25). Moreover, mitochondrial
fragmentation and increased autophagy are observed in neurodegenerative
diseases including Alzheimer and Parkinson diseases
(4,
26-28).
Although inclusion of mitochondria in autophagosomes was once believed to be a
random process, as observed during starvation, studies involving hypoxia,
mitochondrial damage, apoptotic stimuli, or limiting amounts of aerobic
substrates in facultative anaerobes support the concept of selective
mitochondrial autophagy (mitophagy)
(29,
30). In particular,
mitochondrially localized kinases may play an important role in models
involving oxidative mitochondrial injury
(25,
31,
32).Autophagy is involved in the clearance of protein aggregates
(33-35)
and normal regulation of axonal-synaptic morphology
(36). Chronic disruption of
lysosomal function results in accumulation of subtly impaired mitochondria
with decreased calcium buffering capacity
(37), implicating an important
role for autophagy in mitochondrial homeostasis
(37,
38). Recently, Parkin, which
complements the effects of PINK1 deficiency on mitochondrial morphology
(3), was found to promote
autophagy of depolarized mitochondria
(39). Conversely, Beclin
1-independent autophagy/mitophagy contributes to cell death elicited by the PD
toxins 1-methyl-4-phenylpyridinium and 6-OHDA
(25,
28,
31,
32), causing neurite
retraction in cells expressing a PD-linked mutation in leucine-rich repeat
kinase 2 (40). Whereas
properly regulated autophagy plays a homeostatic and neuroprotective role,
excessive or incomplete autophagy creates a condition of “autophagic
stress” that can contribute to neurodegeneration
(28).As mitochondrial fragmentation
(3) and increased mitochondrial
autophagy (4) have been
described in human cells or tissues of PD patients, we investigated whether or
not the engineered loss of PINK1 function could recapitulate these
observations in human neuronal cells (SH-SY5Y). Stable knockdown of endogenous
PINK1 gave rise to mitochondrial fragmentation and increased autophagy and
mitophagy, whereas stable or transient overexpression of PINK1 had the
opposite effect. Autophagy/mitophagy was dependent upon increased
mitochondrial oxidant production and activation of fission. The data indicate
that PINK1 is important for the maintenance of mitochondrial networks,
suggesting that coordinated regulation of mitochondrial dynamics and autophagy
limits cell death associated with loss of PINK1 function. 相似文献
4.
Sophie Pattingre Chantal Bauvy St��phane Carpentier Thierry Levade Beth Levine Patrice Codogno 《The Journal of biological chemistry》2009,284(5):2719-2728
Macroautophagy is a vacuolar lysosomal catabolic pathway that is stimulated
during periods of nutrient starvation to preserve cell integrity. Ceramide is
a bioactive sphingolipid associated with a large range of cell processes. Here
we show that short-chain ceramides (C2-ceramide and
C6-ceramide) and stimulation of the de novo ceramide
synthesis by tamoxifen induce the dissociation of the complex formed between
the autophagy protein Beclin 1 and the anti-apoptotic protein Bcl-2. This
dissociation is required for macroautophagy to be induced either in response
to ceramide or to starvation. Three potential phosphorylation sites,
Thr69, Ser70, and Ser87, located in the
non-structural N-terminal loop of Bcl-2, play major roles in the dissociation
of Bcl-2 from Beclin 1. We further show that activation of c-Jun N-terminal
protein kinase 1 by ceramide is required both to phosphorylate Bcl-2 and to
stimulate macroautophagy. These findings reveal a new aspect of sphingolipid
signaling in up-regulating a major cell process involved in cell adaptation to
stress.Macroautophagy (referred to below as “autophagy”) is a
vacuolar, lysosomal degradation pathway for cytoplasmic constituents that is
conserved in eukaryotic cells
(1–3).
Autophagy is initiated by the formation of a multimembrane-bound autophagosome
that engulfs cytoplasmic proteins and organelles. The last stage in the
process results in fusion with the lysosomal compartments, where the
autophagic cargo undergoes degradation. Basal autophagy is important in
controlling the quality of the cytoplasm by removing damaged organelles and
protein aggregates. Inhibition of basal autophagy in the brain is deleterious,
and leads to neurodegeneration in mouse models
(4,
5). Stimulation of autophagy
during periods of nutrient starvation is a physiological response present at
birth and has been shown to provide energy in various tissues of newborn pups
(6). In cultured cells,
starvation-induced autophagy is an autonomous cell survival mechanism, which
provides nutrients to maintain a metabolic rate and level of ATP compatible
with cell survival (7). In
addition, starvation-induced autophagy blocks the induction of apoptosis
(8). In other contexts, such as
drug treatment and a hypoxic environment, autophagy has also been shown to be
cytoprotective in cancer cells
(9,
10). However, autophagy is
also part of cell death pathways in certain situations
(11). Autophagy can be a
player in apoptosis-independent type-2 cell death (type-1 cell death is
apoptosis), also known as autophagic cell death. This situation has been shown
to occur when the apoptotic machinery is crippled in mammalian cells
(12,
13). Autophagy can also be
part of the apoptotic program, for instance in tumor necrosis
factor-α-induced cell death when NF-κB is inhibited
(14), or in human
immunodeficiency virus envelope-mediated cell death in bystander naive CD4 T
cells (15). Moreover autophagy
has recently been shown to be required for the externalization of
phosphatidylserine, the eat-me signal for phagocytic cells, at the surface of
apoptotic cells (16).The complex relationship between autophagy and apoptosis reflects the
intertwined regulation of these processes
(17,
18). Many signaling pathways
involved in the regulation of autophagy also regulate apoptosis. This
intertwining has recently been shown to occur at the level of the molecular
machinery of autophagy. In fact the anti-apoptotic protein Bcl-2 has been
shown to inhibit starvation-induced autophagy by interacting with the
autophagy protein Beclin 1
(19). Beclin 1 is one of the
Atg proteins conserved from yeast to humans (it is the mammalian orthologue of
yeast Atg6) and is involved in autophagosome formation
(20). Beclin 1 is a platform
protein that interacts with several different partners, including hVps34
(class III phosphatidylinositol 3-kinase), which is responsible for the
synthesis of phosphatidylinositol 3-phosphate. The production of this lipid is
important for events associated with the nucleation of the isolation membrane
before it elongates and closes to form autophagosomes in response to other Atg
proteins, including the Atg12 and
LC32
(microtubule-associated protein light chain 3 is the mammalian orthologue of
the yeast Atg8) ubiquitin-like conjugation systems
(3,
21). Various partners
associated with the Beclin 1 complex modulate the activity of hVps34. For
instance, Bcl-2 inhibits the activity of this enzyme, whereas UVRAG, Ambra-1,
and Bif-1 all up-regulate it
(22,
23).In view of the intertwining between autophagy and apoptosis, it is
noteworthy that Beclin 1 belongs to the BH3-only family of proteins
(24–26).
However, and unlike most of the proteins in this family, Beclin 1 is not able
to trigger apoptosis when its expression is forced in cells
(27). A BH3-mimetic drug,
ABT-737, is able to dissociate the Beclin 1-Bcl-2 complex, and to trigger
autophagy by mirroring the effect of starvation
(25).The sphingolipids constitute a family of bioactive lipids
(28–32)
of which several members, such as ceramide and sphingosine 1-phosphate, are
signaling molecules. These molecules constitute a “sphingolipid
rheostat” that determines the fate of the cell, because in many settings
ceramide is pro-apoptotic and sphingosine 1-phosphate mitigates this apoptotic
effect (31,
32). However, ceramide is also
engaged in a wide variety of other cell processes, such as the formation of
exosomes (33),
differentiation, cell proliferation, and senescence
(34). Recently we showed that
both ceramide and sphingosine 1-phosphate are able to stimulate autophagy
(35,
36). It has also been shown
that ceramide triggers autophagy in a large panel of mammalian cells
(37–39).
However, elucidation of the mechanism by which ceramide stimulates autophagy
is still in its infancy. We have previously demonstrated that ceramide induces
autophagy in breast and colon cancer cells by inhibiting the Class I
phosphatidylinositol 3-phosphate/mTOR signaling pathway, which plays a central
role in inhibiting autophagy
(36). Inhibition of mTOR is
another hallmark of starvation-induced autophagy
(17). This finding led us to
investigate the effect of ceramide on the Beclin 1-Bcl-2 complex. The results
presented here show that ceramide is more potent than starvation in
dissociating the Beclin 1-Bcl-2 complex (see Ref.
40). This dissociation is
dependent on three phosphorylation sites (Thr69, Ser70,
and Ser87) located in a non-structural loop of Bcl-2. Ceramide
induces the c-Jun N-terminal kinase 1-dependent phosphorylation of Bcl-2.
Expression of a dominant negative form of JNK1 blocks Bcl-2 phosphorylation,
and thus the induction of autophagy by ceramide. These findings help to
explain how autophagy is regulated by a major lipid second messenger. 相似文献
5.
Eva Brombacher Simon Urwyler Curdin Ragaz Stefan S. Weber Keiichiro Kami Michael Overduin Hubert Hilbi 《The Journal of biological chemistry》2009,284(8):4846-4856
The causative agent of Legionnaires disease, Legionella
pneumophila, forms a replicative vacuole in phagocytes by means of the
intracellular multiplication/defective organelle trafficking (Icm/Dot) type IV
secretion system and translocated effector proteins, some of which subvert
host GTP and phosphoinositide (PI) metabolism. The Icm/Dot substrate SidC
anchors to the membrane of Legionella-containing vacuoles (LCVs) by
specifically binding to phosphatidylinositol 4-phosphate (PtdIns(4)P). Using a
nonbiased screen for novel L. pneumophila PI-binding proteins, we
identified the Rab1 guanine nucleotide exchange factor (GEF) SidM/DrrA as the
predominant PtdIns(4)P-binding protein. Purified SidM specifically and
directly bound to PtdIns(4)P, whereas the SidM-interacting Icm/Dot substrate
LidA preferentially bound PtdIns(3)P but also PtdIns(4)P, and the L.
pneumophila Arf1 GEF RalF did not bind to any PIs. The PtdIns(4)P-binding
domain of SidM was mapped to the 12-kDa C-terminal sequence, termed
“P4M” (PtdIns4P binding of
SidM/DrrA). The isolated P4M domain is largely helical and
displayed higher PtdIns(4)P binding activity in the context of the
α-helical, monomeric full-length protein. SidM constructs containing P4M
were translocated by Icm/Dot-proficient L. pneumophila and localized
to the LCV membrane, indicating that SidM anchors to PtdIns(4)P on LCVs via
its P4M domain. An L. pneumophila ΔsidM mutant strain
displayed significantly higher amounts of SidC on LCVs, suggesting that SidM
and SidC compete for limiting amounts of PtdIns(4)P on the vacuole. Finally,
RNA interference revealed that PtdIns(4)P on LCVs is specifically formed by
host PtdIns 4-kinase IIIβ. Thus, L. pneumophila exploits
PtdIns(4)P produced by PtdIns 4-kinase IIIβ to anchor the effectors SidC
and SidM to LCVs.The Gram-negative pathogen Legionella pneumophila is the causative
agent of Legionnaires disease, but it evolved as a parasite of various species
of environmental predatory protozoa, including the social amoeba
Dictyostelium discoideum
(1,
2). The human disease is linked
to the inhalation of contaminated aerosols, followed by replication in
alveolar macrophages. To accommodate the transfer between host cells, L.
pneumophila alternates between replicative and transmissive phases, the
regulation of which includes an apparent quorum-sensing system
(3–5).In macrophages and amoebae, L. pneumophila forms a replicative
compartment, the Legionella-containing vacuole
(LCV).3 LCVs avoid
fusion with lysosomes (6),
intercept vesicular traffic at endoplasmic reticulum (ER) exit sites
(7), and fuse with the ER
(8–10).
The uptake of L. pneumophila and formation of LCVs in macrophages and
amoebae depends on the Icm/Dot type IV secretion system (T4SS)
(11–14).
Although more than 100 Icm/Dot substrates (“effector” proteins)
have been identified to date, only few are functionally characterized,
including effectors that interfere with host cell signal transduction, vesicle
trafficking, or apoptotic pathways
(15–18).Two Icm/Dot-translocated substrates, SidM/DrrA
(19,
20) and RalF
(21), have been characterized
as guanine nucleotide exchange factors (GEFs) for the Rho subfamily of small
GTPases. These bacterial GEFs are recruited to and activate their targets on
LCVs. Small GTPases of the Rho subfamily are involved in many eukaryotic
signal transduction pathways and in actin cytoskeleton regulation
(22). Inactive Rho GTPases
bind GDP and a guanine nucleotide dissociation inhibitor (GDI). The GTPases
are activated by removal of the GDI and the exchange of GDP with GTP by GEFs,
which promotes the interaction with downstream effector proteins, such as
protein or lipid kinases and various adaptor proteins. The cycle is closed by
hydrolysis of the bound GTP, which is mediated by GTPase-activating
proteins.SidM is a GEF for Rab1, which is essential for ER to Golgi vesicle
transport, and additionally, SidM acts as a GDI displacement factor (GDF) to
activate Rab1 (23,
24). The function of SidM is
assisted by the Icm/Dot substrate LidA, which also localizes to LCVs. LidA
preferentially binds to activated Rab1, thus supporting the recruitment of
early secretory vesicles by SidM
(19,
20,
23,
25,
26). Another Icm/Dot
substrate, LepB (27),
contributes to Rab1-mediated membrane cycling by inactivating Rab1 through its
GTPase-activating protein function, thus acting as an antagonist of SidM
(24).The Icm/Dot substrate RalF recruits and activates the small GTPase
ADP-ribosylation factor 1 (Arf1), which is involved in retrograde vesicle
transport from Golgi to ER
(21). Dominant negative Arf1
(7,
28) or knockdown of Arf1 by
RNA interference (29) impairs
the formation of LCVs, as well as the recruitment of the Icm/Dot substrate
SidC to the LCV (30).SidC and its paralogue SdcA localize to the LCV membrane
(31), where the proteins
specifically bind to the host cell lipid phosphatidylinositol 4-phosphate
(PtdIns(4)P) (32,
33). Phosphoinositides (PIs)
regulate eukaryotic receptor-mediated signal transduction, actin remodeling,
and membrane dynamics (34,
35). PtdIns(4)P is present on
the cytoplasmic membrane, but localizes preferentially to the
trans-Golgi network (TGN), where this PI is produced by an
Arf-dependent recruitment of PtdIns(4)P kinase IIIβ (PI4K IIIβ)
(36) to promote trafficking
along the secretory pathway. Recently, PtdIns(4)P was found to also mediate
the export of early secretory vesicles from ER exit sites
(37). At present, the L.
pneumophila effector proteins that mediate exploitation of host PI
signaling remain ill defined.In a nonbiased screen for L. pneumophila PI-binding proteins using
different PIs coupled to agarose beads, we identified SidM as a major
PtdIns(4)P-binding effector. We mapped its PtdIns(4)P binding activity to a
novel P4M domain within a 12-kDa C-terminal sequence. SidM constructs,
including the P4M domain, were found to be translocated and bind the LCV
membrane, where the levels of PtdIns(4)P are controlled by PI4K IIIβ. 相似文献
6.
7.
Cell-cell adhesion is a dynamic process that can activate multiple
signaling pathways. These signaling pathways can be regulated through
reversible tyrosine phosphorylation events. The level of tyrosine
phosphorylation of junctional proteins reflects the balance between
protein-tyrosine kinase and protein-tyrosine phosphatase activity. The
receptor-tyrosine phosphatase DEP-1 (CD148/PTP-η) has been implicated in
cell growth and differentiation as well as in regulating phosphorylation of
junctional proteins. However, the role of DEP-1 in regulating tight junction
phosphorylation and the integrity of cell-cell junctions is still under
investigation. In this study, we used a catalytically dead substrate-trapping
mutant of DEP-1 to identify potential substrates at cell-cell junctions. We
have shown that in epithelial cells the trapping mutant of DEP-1 interacts
with the tight junction proteins occludin and ZO-1 in a tyrosine
phosphorylation-dependent manner. In contrast, PTP-PEST, Shp2, and PTPμ did
not interact with these proteins, suggesting that the interaction of DEP-1
with occludin and ZO-1 is specific. In addition, occludin and ZO-1 were
dephosphorylated by DEP-1 but not these other phosphatases in vitro.
Overexpression of DEP-1 increased barrier function as measured by
transepithelial electrical resistance and also reduced paracellular flux of
fluorescein isothiocyanate-dextran following a calcium switch. Reduced DEP-1
expression by small interfering RNA had a small but significant increase in
junction permeability. These data suggest that DEP-1 can modify the
phosphorylation state of tight junction proteins and play a role in regulating
permeability.Tight junctions are the most apical of junctions formed by epithelia and
provide a regulated barrier to paracellular transport of ions, solutes,
macromolecules, and even other cells. In addition, tight junctions act as a
“fence” within the plane of the membrane, dividing the apical and
basolateral domains of polarized epithelial cells. These junctions play an
important role in the regulation of multiple cellular processes including cell
differentiation, proliferation, and polarity (for reviews see Refs.
1 and
2). Functional tight junctions
are characterized by the presence of membrane spanning proteins (claudins,
occludin, and JAMs), which interact with cytoplasmic proteins (AF-6 and ZO-1,
-2, -3), regulating assembly and maintenance of tight junctions. Occludin
spans the membrane four times and was the first transmembrane component of the
tight junction to be identified
(3). It has two extracellular
regions, an intracellular loop, as well as both an N- and C-terminal
cytoplasmic tail (3). The
C-terminal tail of occludin binds directly to the ZO family of proteins, which
link the protein complex to the actin cytoskeleton
(4–8).
The long C-terminal domain is rich in serine, threonine, and tyrosine residues
(9). In fact, several kinases
and phosphatases interact with and modulate the phosphorylation state of tight
junction proteins
(10–14).
Serine and threonine phosphorylation of occludin is abundant in epithelia with
intact junctions, whereas tyrosine phosphorylation is undetectable
(15). However, tyrosine
phosphorylation of occludin is associated with a decrease in transepithelial
electrical resistance
(TER)2
(16,
17) and loss of protein
localization at the tight junction
(18). Increases in tyrosine
phosphorylation of occludin and ZO-1 result in the dissociation of the
occludin-ZO-1 complex and reduces the localization at the tight junction of
these proteins (12,
19). These data suggest that
the phosphorylation state of tight junction proteins can affect the integrity
of the tight junction complex and therefore the integrity of the tight
junction itself. Both serine and threonine kinases and phosphatases bind to
and act on TJ proteins (reviewed in Ref.
20). Previous studies have
identified that c-Src and c-Yes are protein-tyrosine kinases, which act on the
TJ, however, to date no protein-tyrosine phosphatases have been specifically
characterized as acting on TJ proteins
(11–13,
21).Similarly, the other major junction of epithelia, the adherens junction
(AJ), is also regulated by tyrosine phosphorylation. Increased tyrosine
phosphorylation of the AJ decreases the stability of the cadherin-catenin
complex, disrupting the association with the cytoskeleton and reducing
junctional integrity
(22–24).
Therefore, these studies suggest that maintenance of junctional integrity for
both the TJ and AJ is regulated in part by reversible tyrosine phosphorylation
that results from a competing balance of protein-tyrosine kinase and
protein-tyrosine phosphatase (PTP) activity. Several PTPs have been localized
to AJs and shown to bind components of the cadherin-catenin complex. The PTPs
in AJs include receptor-PTPs (PTPμ, DEP-1, and vascular endothelial-PTP),
as well as cytosolic PTPs (PTP1B and Shp-2)
(25–30).
The high concentration of PTPs at cell-cell junctions indicates the importance
of maintaining low levels of tyrosine phosphorylation except when the
junctions need to be remodeled or disassembled.DEP-1 (density-enhanced
phosphatase-1) is a receptor PTP that was first cloned
from a human cDNA library and named based on the observation that its
expression was elevated with increasing cell density
(31). Also known as PTP-η,
PTPRJ, and CD148, DEP-1 is comprised of an extracellular domain of eight
fibronectin type III repeats, a transmembrane domain, and a single cytoplasmic
catalytic domain. The protein is ubiquitously expressed
(32), indicating its potential
involvement in a large number of diverse signaling pathways. DEP-1 is involved
in regulating the differentiation of epithelial cells
(33–36),
as well as controlling cell growth and adhesion
(33,
34). In addition, DEP-1 is
able to attenuate the cellular response to growth factors through the
preferential dephosphorylation of several growth factor receptors, suggesting
that DEP-1 can selectively dephosphorylate certain tyrosines to more finely
control signaling
(37–41).In addition to its role in proliferation and differentiation, DEP-1
localizes to areas of cell-cell adhesion in endothelial and epithelial cells,
overlapping with the AJ marker vascular endothelial-cadherin in endothelia
(42). Interaction with p120
catenin as well as other members of the catenin family also supports the
hypothesis that DEP-1 plays a role in regulating AJ protein phosphorylation
(27,
40). In the current study, we
investigated whether adjacent tight junction proteins are also substrates of
DEP-1. We now demonstrate that the substrate-trapping mutant of DEP-1
interacts with the tight junction proteins occludin and ZO-1. The association
of DEP-1 with occludin and ZO-1 is specific to DEP-1 and not other
phosphatases tested. In addition, DEP-1 is able to dephosphorylate occludin
and ZO-1 indicating that these tight junction proteins are substrates of
DEP-1. Furthermore, increased expression of DEP-1 enhances barrier function as
junctions reform following a calcium switch and loss of DEP-1 levels increased
the permeability of a stable epithelial monolayer. Together these results
indicate that ZO-1 and occludin are substrates of DEP-1 and imply a role for
DEP-1 in influencing the phosphorylation state of tight junction proteins and
junction permeability. 相似文献
8.
9.
Formin-homology (FH) 2 domains from formin proteins associate processively
with the barbed ends of actin filaments through many rounds of actin subunit
addition before dissociating completely. Interaction of the actin
monomer-binding protein profilin with the FH1 domain speeds processive barbed
end elongation by FH2 domains. In this study, we examined the energetic
requirements for fast processive elongation. In contrast to previous
proposals, direct microscopic observations of single molecules of the formin
Bni1p from Saccharomyces cerevisiae labeled with quantum dots showed
that profilin is not required for formin-mediated processive elongation of
growing barbed ends. ATP-actin subunits polymerized by Bni1p and profilin
release the γ-phosphate of ATP on average >2.5 min after becoming
incorporated into filaments. Therefore, the release of γ-phosphate from
actin does not drive processive elongation. We compared experimentally
observed rates of processive elongation by a number of different FH2 domains
to kinetic computer simulations and found that actin subunit addition alone
likely provides the energy for fast processive elongation of filaments
mediated by FH1FH2-formin and profilin. We also studied the role of FH2
structure in processive elongation. We found that the flexible linker joining
the two halves of the FH2 dimer has a strong influence on dissociation of
formins from barbed ends but only a weak effect on elongation rates. Because
formins are most vulnerable to dissociation during translocation along the
growing barbed end, we propose that the flexible linker influences the
lifetime of this translocative state.Formins are multidomain proteins that assemble unbranched actin filament
structures for diverse processes in eukaryotic cells (reviewed in Ref.
1). Formins stimulate
nucleation of actin filaments and, in the presence of the actin
monomer-binding protein profilin, speed elongation of the barbed ends of
filaments
(2-6).
The ability of formins to influence elongation depends on the ability of
single formin molecules to remain bound to a growing barbed end through
multiple rounds of actin subunit addition
(7,
8). To stay associated during
subunit addition, a formin molecule must translocate processively on the
barbed end as each actin subunit is added
(1,
9-12).
This processive elongation of a barbed end by a formin is terminated when the
formin dissociates stochastically from the growing end during translocation
(4,
10).The formin-homology
(FH)2 1 and
2 domains are the best conserved domains of formin proteins
(2,
13,
14). The FH2 domain is the
signature domain of formins, and in many cases, is sufficient for both
nucleation and processive elongation of barbed ends
(2-4,
7,
15). Head-to-tail homodimers
of FH2 domains (12,
16) encircle the barbed ends
of actin filaments (9). In
vitro, association of barbed ends with FH2 domains slows elongation by
limiting addition of free actin monomers. This “gating” behavior
is usually explained by a rapid equilibrium of the FH2-associated end between
an open state competent for actin monomer association and a closed state that
blocks monomer binding (4,
9,
17).Proline-rich FH1 domains located N-terminal to FH2 domains are required for
profilin to stimulate formin-mediated elongation. Individual tracks of
polyproline in FH1 domains bind 1:1 complexes of profilin-actin and transfer
the actin directly to the FH2-associated barbed end to increase processive
elongation rates
(4-6,
8,
10,
17).Rates of elongation and dissociation from growing barbed ends differ widely
for FH1FH2 fragments from different formin homologs
(4). We understand few aspects
of FH1FH2 domains that influence gating, elongation or dissociation. In this
study, we examined the source of energy for formin-mediated processive
elongation, and the influence of FH2 structure on elongation and dissociation
from growing ends. In contrast to previous proposals
(6,
18), we found that fast
processive elongation mediated by FH1FH2-formins is not driven by energy from
the release of the γ-phosphate from ATP-actin filaments. Instead, the
data show that the binding of an actin subunit to the barbed end provides the
energy for processive elongation. We found that in similar polymerizing
conditions, different natural FH2 domains dissociate from growing barbed ends
at substantially different rates. We further observed that the length of the
flexible linker between the subunits of a FH2 dimer influences dissociation
much more than elongation. 相似文献
10.
Masataka Horiuchi Kosei Takeuchi Nobuo Noda Nobuyuki Muroya Toru Suzuki Takahisa Nakamura Junko Kawamura-Tsuzuku Kiyohiro Takahasi Tadashi Yamamoto Fuyuhiko Inagaki 《The Journal of biological chemistry》2009,284(19):13244-13255
The Tob/BTG family is a group of antiproliferative proteins containing two
highly homologous regions, Box A and Box B. These proteins all associate with
CCR4-associated factor 1 (Caf1), which belongs to the ribonuclease D (RNase D)
family of deadenylases and is a component of the CCR4-Not deadenylase complex.
Here we determined the crystal structure of the complex of the N-terminal
region of Tob and human Caf1 (hCaf1). Tob exhibited a novel fold, whereas
hCaf1 most closely resembled the catalytic domain of yeast Pop2 and human
poly(A)-specific ribonuclease. Interestingly, the association of hCaf1 was
mediated by both Box A and Box B of Tob. Cell growth assays using both
wild-type and mutant proteins revealed that deadenylase activity of Caf1 is
not critical but complex formation is crucial to cell growth inhibition. Caf1
tethers Tob to the CCR4-Not deadenylase complex, and thereby Tob gathers
several factors at its C-terminal region, such as poly(A)-binding proteins, to
exert antiproliferative activity.The Tob/BTG family (also called the APRO family) is a group of
antiproliferative proteins (1,
2) consisting of Tob
(3), Tob2
(4), BTG1
(5), BTG2/Tis21/PC3
(6-8),
PC3B (9), and ANA/BTG3
(10,
11) in mammalian cells,
in Drosophila, and FOG-3 in Caenorhabditis elegans
( AF17746412). A recent genome project
reported that the BTG/Tob family protein had already existed in
Choanoflagellida Monosiga brevicollis MX1. The N-terminal region of
the Tob/BTG family proteins is conserved and includes two highly homologous
regions, Box A and Box B. The Tob/BTG family proteins are involved in cell
cycle regulation in a variety of cells such as T lymphocytes, fibroblasts,
epithelial cells, and germ cells. In Tob-deficient mice, the incidence of
liver tumors is higher than in wild-type mice. Furthermore, because the levels
of tob expression are often repressed in human lung cancers,
suppression of its expression is thought to contribute to tumor progression
(13).The antiproliferative activities of the Tob/BTG family proteins are due to
their association with target proteins in cells. For example, Tob associates
with SMAD family proteins and acts as a negative regulator of SMAD signaling.
In osteoblasts, this negative regulation occurs via association with SMAD 1,
5, 6, and 8 (14,
15), and via association with
SMAD 2 and 4 in anergic quiescent T cells
(16). Tob/BTG family proteins
also bind to protein arginine methyltransferase, which regulates chromatin
assembly by histone methylation
(17). Much evidence has been
accumulated to suggest that CCR4-associated factor 1
(Caf1),2 also known as
Cnot7 and involved in the CCR4-Not deadenylase complex, is a common binding
partner of the Tob/BTG family proteins
(4,
18-21).
To reveal the functions of Caf1 in vivo, caf1-/- mice have
been generated in two groups. Male caf1-deficient mice are infertile
because of a malfunction of the testicular somatic cells that leads to a
defect in spermatogenesis (22,
23). Genetic analysis of the
nematode C. elegans also suggests that FOG3 (Tob orthologue)
interacts with CCF1, the C. elegans homologue of Caf1, and that this
interaction is essential for germ cells to initiate spermatogenesis
(24).Mouse and human Caf1 (mCaf1 and hCaf1) were found as homologues of yeast
Pop2, a component of the CCR4-Not complex
(18,
25). Yeast Pop2 displays weak
RNase activity but enhances the deadenylation of the poly(A) tail of mRNA by
the CCR4-Not deadenylase complex
(26-29).
The primary structure of mammalian Caf1 is related to that of the ribonuclease
D (RNase D) family, and all of the active site residues are well conserved
(30). Indeed, both mCaf1 and
hCaf1 have deadenylase activity
(31-33).Although the relationship between cell cycle repression and poly(A)
deadenylation is not well understood, mRNA degradation and synthesis are major
events in maintaining the cell cycle
(34). The mRNAs in a
eukaryotic cell have a wide range of half-lives. Degradation of mRNA is
initiated by shortening of the poly(A) tail. Thereafter, the 5′-cap
structure is removed and the remaining portion of the mRNA is rapidly
degraded. The degradation of eukaryotic mRNAs is regulated precisely at each
stage of the cell cycle. Tob was reported to associate with inducible
poly(A)-binding protein (iPABP) and to abrogate the translation of
interleukin-2 mRNA in vitro
(35). Recent reports also
showed that Tob and BTG2 interact with the CCR4-Not deadenylase complex using
the Tob/BTG2 domain and the cytoplasmic poly(A)-binding protein (PABPC1) using
the C-terminal tail and enhanced mRNA degradation
(36-38).To help elucidate the relationship between the antiproliferative activity
of Tob and the degradation of the poly(A) tail, we determined the crystal
structure of the Tob-hCaf1 complex. We found that hCaf1 has a structure
similar to yeast Pop2 and human PARN of deadenylases, exonuclease I, and the
Klenow fragment of DNA polymerase I from Escherichia coli. In
contrast, Tob has a novel structure. Specifically, Box A and Box B mediate the
interaction between Tob and hCaf1. Cell growth assays using the wild and
mutant proteins, together with the structural studies, revealed that the
complex formation is crucial to cell growth inhibition. 相似文献
11.
12.
Zemfira Karamysheva Laura A. Diaz-Martinez Sara E. Crow Bing Li Hongtao Yu 《The Journal of biological chemistry》2009,284(3):1772-1780
Shugoshin 1 (Sgo1) protects centromeric sister-chromatid cohesion in early
mitosis and, thus, prevents premature sister-chromatid separation. The protein
level of Sgo1 is regulated during the cell cycle; it peaks in mitosis and is
down-regulated in G1/S. Here we show that Sgo1 is degraded during
the exit from mitosis, and its degradation depends on the anaphase-promoting
complex/cyclosome (APC/C). Overexpression of Cdh1 reduces the protein levels
of ectopically expressed Sgo1 in human cells. Sgo1 is ubiquitinated by APC/C
bound to Cdh1 (APC/CCdh1) in vitro. We have further
identified two functional degradation motifs in Sgo1; that is, a KEN
(Lys-Glu-Asn) box and a destruction box (D box). Although removal of either
motif is not sufficient to stabilize Sgo1, Sgo1 with both KEN box and D box
deleted is stable in cells. Surprisingly, mitosis progresses normally in the
presence of non-degradable Sgo1, indicating that degradation of Sgo1 is not
required for sister-chromatid separation or mitotic exit. Finally, we show
that the spindle checkpoint kinase Bub1 contributes to the maintenance of Sgo1
steady-state protein levels in an APC/C-independent mechanism.Loss of sister-chromatid cohesion triggers chromosome segregation in
mitosis and occurs in two steps in vertebrate cells
(1-3).
In prophase, cohesin is phosphorylated by mitotic kinases including Plk1 and
removed from chromosome arms
(1,
4). Then, cleavage of
centromeric cohesin by separase takes place at the metaphase-to-anaphase
transition to allow sister-chromatid separation
(5). The shugoshin (Sgo) family
of proteins plays an important role in the protection of centromeric cohesion
(6,
7). Human cells depleted of
Sgo1 by RNAi undergo massive chromosome missegregation
(8-11).
In cells with compromised Sgo1 function, centromeric cohesin is improperly
phosphorylated and removed (4,
11), resulting in premature
sister-chromatid separation. It has been shown recently that Sgo1 collaborates
with PP2A to counteract the action of Plk1 and other mitotic kinases and to
protect centromeric cohesin from premature removal
(12-14).
In addition, Sgo1 has also been shown to promote stable
kinetochore-microtubule attachment and sense tension across sister
kinetochores (8,
15). Thus, Sgo1 is crucial for
mitotic progression and chromosome segregation.Orderly progression through mitosis is regulated by the anaphase-promoting
complex/cyclosome
(APC/C),2 a large
multiprotein ubiquitin ligase that targets key mitotic regulators for
destruction by the proteasome
(16). APC/C selects substrates
for ubiquitination by using the Cdc20 or Cdh1 activator proteins to recognize
specific sequences called APC/C degrons within target proteins
(17). Several APC/C degrons
have been characterized, including the destruction box (D box) and the
Lys-Glu-Asn box (KEN box) (18,
19). The D box, with the
consensus amino acid sequence of RXXLXXXN(X
indicates any amino acid), are found in many APC/C substrates, including
mitotic cyclins and are essential for their ubiquitin-mediated destruction.
The KEN box, which contains a consensus KEN motif, is also found in several
APC/C substrates and is preferentially but not exclusively recognized by
APC/CCdh1. When APC/C is active, it directs progression through and
exit from mitosis by catalyzing the ubiquitination and timely destruction of
mitotic regulators, including cyclin A, cyclin B, and the separase inhibitor
securin (16). The APC/C
activity needs to be tightly controlled to prevent unscheduled substrate
degradation. An important mechanism for APC/C regulation is the spindle
checkpoint, which prevents the activation of APC/C and destruction of its
substrates in response to kinetochores that have not properly attached to the
mitotic spindle (20).Recent evidence shows that Sgo1 is a substrate of APC/C, and its protein
levels oscillate during the cell cycle
(8,
9). In this article we study
the degradation of Sgo1 in human cells. We show that Sgo1 is degraded during
mitotic exit, and this degradation depends on APC/CCdh1. We further
show that both KEN and D boxes are required for Sgo1 degradation in
vivo and ubiquitination in vitro. Removal of these motifs
stabilizes Sgo1 in vivo. The prolonged presence of stable Sgo1
protein in human cells does not change the kinetics of chromosome segregation
and mitotic exit. Therefore, a timely scheduled degradation of Sgo1 takes
place but is not required for mitotic exit. Finally, we show that Bub1
regulates Sgo1 protein levels through a mechanism that does not involve
APC/C-mediated degradation. 相似文献
13.
Ivana I. Knezevic Sanda A. Predescu Radu F. Neamu Matvey S. Gorovoy Nebojsa M. Knezevic Cordus Easington Asrar B. Malik Dan N. Predescu 《The Journal of biological chemistry》2009,284(8):5381-5394
It is known that platelet-activating factor (PAF) induces severe
endothelial barrier leakiness, but the signaling mechanisms remain unclear.
Here, using a wide range of biochemical and morphological approaches applied
in both mouse models and cultured endothelial cells, we addressed the
mechanisms of PAF-induced disruption of interendothelial junctions (IEJs) and
of increased endothelial permeability. The formation of interendothelial gaps
filled with filopodia and lamellipodia is the cellular event responsible for
the disruption of endothelial barrier. We observed that PAF ligation of its
receptor induced the activation of the Rho GTPase Rac1. Following PAF
exposure, both Rac1 and its guanine nucleotide exchange factor Tiam1 were
found associated with a membrane fraction from which they
co-immunoprecipitated with PAF receptor. In the same time frame with
Tiam1-Rac1 translocation, the junctional proteins ZO-1 and VE-cadherin were
relocated from the IEJs, and formation of numerous interendothelial gaps was
recorded. Notably, the response was independent of myosin light chain
phosphorylation and thus distinct from other mediators, such as histamine and
thrombin. The changes in actin status are driven by the PAF-induced localized
actin polymerization as a consequence of Rac1 translocation and activation.
Tiam1 was required for the activation of Rac1, actin polymerization,
relocation of junctional associated proteins, and disruption of IEJs. Thus,
PAF-induced IEJ disruption and increased endothelial permeability requires the
activation of a Tiam1-Rac1 signaling module, suggesting a novel therapeutic
target against increased vascular permeability associated with inflammatory
diseases.The endothelial barrier is made up of endothelial cells
(ECs)4 connected to
each other by interendothelial junctions (IEJs) consisting of protein
complexes organized as tight junctions (TJs) and adherens junctions (AJs). In
addition, the focal adhesion complex located at the basal plasma membrane
enables firm contact of ECs with the underlying basement membrane and also
contributes to the barrier function
(1-3).
The glycocalyx, the endothelial monolayer, and the basement membrane all
together constitute the vascular barrier.The structural integrity of the ECs along with their proper functionality
are the two most important factors controlling the tightness of the
endothelial barrier. Changes affecting these factors cause loss of barrier
restrictiveness and leakiness. Therefore, defining and understanding the
cellular and molecular mechanisms controlling these processes is of paramount
importance. Increased width of IEJs in response to permeability-increasing
mediators (4) regulates the
magnitude of transendothelial exchange of fluid and solutes. Disruption of
IEJs and the resultant barrier leakiness contribute to the genesis of diverse
pathological conditions, such as inflammation
(5), metastasis
(6,
7), and uncontrolled
angiogenesis (8,
9).Accumulated evidence demonstrated that IEJs changes are responsible for
increased or decreased vascular permeability, and the generally accepted
mechanism responsible for them was the myosin light chain (MLC)-mediated
contraction of ECs (5,
10). However, published
evidence showed that an increase in vascular permeability could be obtained
without a direct involvement of any contractile mechanism
(11-16).The main component of the vascular barrier, the ECs, has more than 10% of
their total protein represented by actin
(17), which under
physiological salt concentrations subsists as monomers (G-actin) and assembled
into filaments (F-actin). A large number of actin-interacting proteins may
modulate the assembly, disassembly, and organization of G-actin and of actin
filaments within a given cell type. Similar to the complexity of
actin-interacting proteins found in other cell types, the ECs utilize their
actin binding proteins to stabilize the endothelial monolayer in order to
efficiently function as a selective barrier
(11). In undisturbed ECs, the
actin microfilaments are organized as different networks with distinctive
functional and morphological characteristics: the peripheral filaments also
known as peripheral dense band (PDB), the cytoplasmic fibers identified as
stress fibers (SF), and the actin from the membrane cytoskeleton
(18). The peripheral web,
localized immediately under the membrane, is associated with (i) the luminal
plasmalemma (on the apical side), (ii) the IEJ complexes on the lateral
surfaces, and (iii) the focal adhesion complexes on the abluminal side (the
basal part) of polarized ECs. The SF reside inside the endothelial cytoplasm
and are believed to be directly connected with the plasmalemma proper on the
luminal as well as on the abluminal side of the cell. As described, the
endothelial actin cytoskeleton (specifically the SF) seems to be a stable
structure helping the cells to remain flat under flow
(19). It is also established
that the actin fibers participate in correct localization of different
junctional complexes while keeping them in place
(20). However, it was
suggested that the dynamic equilibrium between F- and G-actin might modulate
the tightness of endothelial barrier in response to different challenges
(13).Mediators effective at nanomolar concentrations or less that disrupt the
endothelial barrier and increase vascular permeability include C2 toxin of
Clostridium botulinum, vascular permeability factor, better known as
vascular endothelial growth factor, and PAF
(21). C2 toxin increases
endothelial permeability by ribosylating monomeric G-actin at Arg-177
(22). This results in the
impairment of actin polymerization
(23), followed by rounding of
ECs (16) and the disruption of
junctional integrity. Vascular permeability factor was shown to open IEJs by
redistribution of junctional proteins
(24,
25) and by interfering with
the equilibrium of actin pools
(26). PAF
(1-O-alkyl-2-acetyl-sn-glycero-3-phosphocoline), a naturally
synthesized phospholipid is active at 10-10 m or less
(27). PAF is synthesized by
and acts on a variety of cell types, including platelets
(28), neutrophils
(29), monocytes
(30), and ECs
(31). PAF-mediated activation
of ECs induced cell migration
(32), angiogenesis
(7), and vascular
hyperpermeability (33)
secondary to disassembly of IEJs
(34). The effects of PAF on
the endothelium are initiated through a G protein-coupled receptor (PAF-R)
localized at the plasmalemma, in a large endosomal compartment inside the cell
(34), and also in the nuclear
membrane (35). In ECs, PAF-R
was shown to signal through Gαq and downstream activation of
phospholipase C isozymes (PLCβ3 and PLCγ1),
and via cSrc (32,
36). Studies have shown that
PAF challenge induced endothelial actin cytoskeletal rearrangement
(37) and marked vascular
leakiness (38); however, the
signaling pathways have not been elucidated.Therefore, in the present study, we carried out a systematic analysis of
PAF-induced morphological and biochemical changes of endothelial barrier
in vivo and in cultured ECs. We found that the opening of endothelial
barrier and the increased vascular leakiness induced by PAF are the result of
a shift in actin pools without involvement of EC contraction, followed by a
redistribution of tight junctional associated protein ZO-1 and adherens
junctional protein VE-cadherin. 相似文献
14.
15.
16.
17.
As obligate intracellular parasites, viruses exploit diverse cellular
signaling machineries, including the mitogen-activated protein-kinase pathway,
during their infections. We have demonstrated previously that the open reading
frame 45 (ORF45) of Kaposi sarcoma-associated herpesvirus interacts with p90
ribosomal S6 kinases (RSKs) and strongly stimulates their kinase activities
(Kuang, E., Tang, Q., Maul, G. G., and Zhu, F.
(2008) J. Virol. 82
,1838
-1850). Here, we define the
mechanism by which ORF45 activates RSKs. We demonstrated that binding of ORF45
to RSK increases the association of extracellular signal-regulated kinase
(ERK) with RSK, such that ORF45, RSK, and ERK formed high molecular mass
protein complexes. We further demonstrated that the complexes shielded active
pERK and pRSK from dephosphorylation. As a result, the complex-associated RSK
and ERK were activated and sustained at high levels. Finally, we provide
evidence that this mechanism contributes to the sustained activation of ERK
and RSK in Kaposi sarcoma-associated herpesvirus lytic replication.The extracellular signal-regulated kinase
(ERK)2
mitogen-activated protein kinase (MAPK) signaling pathway has been implicated
in diverse cellular physiological processes including proliferation, survival,
growth, differentiation, and motility
(1-4)
and is also exploited by a variety of viruses such as Kaposi
sarcoma-associated herpesvirus (KSHV), human cytomegalovirus, human
immunodeficiency virus, respiratory syncytial virus, hepatitis B virus,
coxsackie, vaccinia, coronavirus, and influenza virus
(5-17).
The MAPK kinases relay the extracellular signaling through sequential
phosphorylation to an array of cytoplasmic and nuclear substrates to elicit
specific responses (1,
2,
18). Phosphorylation of MAPK
is reversible. The kinetics of deactivation or duration of signaling dictates
diverse biological outcomes
(19,
20). For example, sustained
but not transient activation of ERK signaling induces the differentiation of
PC12 cells into sympathetic-like neurons and transformation of NIH3T3 cells
(20-22).
During viral infection, a unique biphasic ERK activation has been observed for
some viruses (an early transient activation triggered by viral binding or
entry and a late sustained activation correlated with viral gene expression),
but the responsible viral factors and underlying mechanism for the sustained
ERK activation remain largely unknown
(5,
8,
13,
23).The p90 ribosomal S6 kinases (RSKs) are a family of serine/threonine
kinases that lie at the terminus of the ERK pathway
(1,
24-26).
In mammals, four isoforms are known, RSK1 to RSK4. Each one has two
catalytically functional kinase domains, the N-terminal kinase domain (NTKD)
and C-terminal kinase domain (CTKD) as well as a linker region between the
two. The NTKD is responsible for phosphorylation of exogenous substrates, and
the CTKD and linker region regulate RSK activation
(1,
24,
25). In quiescent cells ERK
binds to the docking site in the C terminus of RSK
(27-29).
Upon mitogen stimulation, ERK is activated by its upstream MAPK/ERK kinase
(MEK). The active ERK phosphorylates Thr-359/Ser-363 of RSK in the linker
region (amino acid numbers refer to human RSK1) and Thr-573 in the CTKD
activation loop. The activated CTKD then phosphorylates Ser-380 in the linker
region, creating a docking site for 3-phosphoinositide-dependent protein
kinase-1. The 3-phosphoinositide-dependent protein kinase-1 phosphorylates
Ser-221 of RSK in the activation loop and activates the NTKD. The activated
NTKD autophosphorylates the serine residue near the ERK docking site, causing
a transient dissociation of active ERK from RSK
(25,
26,
28). The stimulation of
quiescent cells by a mitogen such as epidermal growth factor or a phorbol
ester such as 12-O-tetradecanoylphorbol-13-acetate (TPA) usually
results in a transient RSK activation that lasts less than 30 min. RSKs have
been implicated in regulating cell survival, growth, and proliferation.
Mutation or aberrant expression of RSK has been implicated in several human
diseases including Coffin-Lowry syndrome and prostate and breast cancers
(1,
24,
25,
30-32).KSHV is a human DNA tumor virus etiologically linked to Kaposi sarcoma,
primary effusion lymphoma, and a subset of multicentric Castleman disease
(33,
34). Infection and
reactivation of KSHV activate multiple MAPK pathways
(6,
12,
35). Noticeably, the ERK/RSK
activation is sustained late during KSHV primary infection and reactivation
from latency (5,
6,
12,
23), but the mechanism of the
sustained ERK/RSK activation is unclear. Recently, we demonstrated that ORF45,
an immediate early and also virion tegument protein of KSHV, interacts with
RSK1 and RSK2 and strongly stimulates their kinase activities
(23). We also demonstrated
that the activation of RSK plays an essential role in KSHV lytic replication
(23). In the present study we
determined the mechanism of ORF45-induced sustained ERK/RSK activation. We
found that ORF45 increases the association of RSK with ERK and protects them
from dephosphorylation, causing sustained activation of both ERK and RSK. 相似文献
18.
Bertha C. Elias Takuya Suzuki Ankur Seth Francesco Giorgianni Gautam Kale Le Shen Jerrold R. Turner Anjaparavanda Naren Dominic M. Desiderio Radhakrishna Rao 《The Journal of biological chemistry》2009,284(3):1559-1569
Occludin is phosphorylated on tyrosine residues during the oxidative
stress-induced disruption of tight junction, and in vitro
phosphorylation of occludin by c-Src attenuates its binding to ZO-1. In the
present study mass spectrometric analyses of C-terminal domain of occludin
identified Tyr-379 and Tyr-383 in chicken occludin as the phosphorylation
sites, which are located in a highly conserved sequence of occludin, YETDYTT;
Tyr-398 and Tyr-402 are the corresponding residues in human occludin. Deletion
of YETDYTT motif abolished the c-Src-mediated phosphorylation of occludin and
the regulation of ZO-1 binding. Y398A and Y402A mutations in human occludin
also abolished the c-Src-mediated phosphorylation and regulation of ZO-1
binding. Y398D/Y402D mutation resulted in a dramatic reduction in ZO-1 binding
even in the absence of c-Src. Similar to wild type occludin, its Y398A/Y402A
mutant was localized at the plasma membrane and cell-cell contact sites in
Rat-1 cells. However, Y398D/Y402D mutants of occludin failed to localize at
the cell-cell contacts. Calcium-induced reassembly of Y398D/Y402D mutant
occludin in Madin-Darby canine kidney cells was significantly delayed compared
with that of wild type occludin or its T398A/T402A mutant. Furthermore,
expression of Y398D/Y402D mutant of occludin sensitized MDCK cells for
hydrogen peroxide-induced barrier disruption. This study reveals a unique
motif in the occludin sequence that is involved in the regulation of ZO-1
binding by reversible phosphorylation of specific Tyr residues.Epithelial tight junctions
(TJs)2 form a
selective barrier to the diffusion of toxins, allergens, and pathogens from
the external environment into the tissues in the gastrointestinal tract, lung,
liver, and kidney (1).
Disruption of TJs is associated with the gastrointestinal diseases such as
inflammatory bowel disease, celiac disease, infectious enterocolitis, and
colon cancer
(2–4)
as well as in diseases of lung and kidney
(5,
6). Numerous inflammatory
mediators such as tumor necrosis factor α, interferon γ, and
oxidative stress
(7–12)
are known to disrupt the epithelial TJs and the barrier function. Several
studies have indicated that hydrogen peroxide disrupts the TJs in intestinal
epithelium by a tyrosine kinase-dependent mechanism
(11,
12).Four types of integral proteins, occludin, claudins, junctional adhesion
molecules, and tricellulin are associated with TJs. Occludin, claudins, and
tricellulin are tetraspan proteins, and their extracellular domains interact
with homotypic domains of the adjacent cells
(1,
2,
13). The intracellular domains
of these proteins interact with a variety of soluble proteins such as ZO-1,
ZO-2, ZO-3, 7H6, cingulin, and symplekin
(14–23);
this protein complex interacts with the perijunctional actomyosin ring. The
interactions among TJ proteins are essential for the assembly and the
maintenance of TJs. Therefore, regulation of the interactions among TJ
proteins may regulate the TJ integrity. A significant body of evidence
indicates that numerous signaling molecules are associated with the TJs.
Protein kinases and protein phosphatases such as protein kinase Cζ
(PKCζ), PKCι/λ
(24), c-Src
(25), c-Yes
(26,
27), mitogen-activated protein
kinase (28), PP2A, and PP1
(29) interact with TJs,
indicating that TJs are dynamically regulated by intracellular signal
transduction involving protein phosphorylation. Additionally, other signaling
molecules such as calcium
(30), phosphatidylinositol
3-kinase (31), Rho
(32), and Rac
(33) are involved in the
regulation of TJs.Occludin, a ∼65-kDa protein, has been well characterized to be
assembled into the TJs. Although occludin knock-out mice showed the formation
of intact TJs in different epithelia
(34), numerous studies have
emphasized that it plays an important role in the regulation of TJ integrity.
Occludin spans the membrane four times to form two extracellular loops and one
intracellular loop, and the N-terminal and C-terminal domains hang into the
intracellular compartment
(35–37).
In epithelium with intact TJs, occludin is highly phosphorylated on Ser and
Thr residues (38), whereas Tyr
phosphorylation is undetectable. However, the disruption of TJs in Caco-2 cell
monolayers by oxidative stress and acetaldehyde leads to Tyr phosphorylation
of occludin; the tyrosine kinase inhibitors attenuate the disruption of TJs
(39,
40). Furthermore, a previous
in vitro study demonstrated that Tyr phosphorylation of the
C-terminal domain of occludin leads to the loss of its interaction with ZO-1
and ZO-3 (25).In the present study we identified the Tyr residues in occludin that are
phosphorylated by c-Src and determined their role in regulated interaction
between occludin and ZO-1 and its assembly into the TJs. Results show that 1)
Tyr-379 and Tyr-383 in chicken occludin and Tyr-398 and Tyr-402 in human
occludin are the exclusive sites of phosphorylation by c-Src, and these Tyr
residues are located in a highly conserved sequence of occludin, YET-DYTT, 2)
deletion of YEDTYTT or point mutation of Tyr-398 and Tyr-402 in human occludin
attenuates the phosphorylation-dependent regulation of ZO-1 binding, 3)
Y398D/Y402D mutation of human occludin leads to loss of ZO-1 binding and
prevents its translocation to the plasma membrane and cell-cell contact sites
in Rat-1 cells, 4) Y398D/Y402D mutation of occludin delays its assembly into
the intercellular junctions during the calcium-induced assembly of TJs, and 5)
expression of Y398D/Y402D mutant occludin sensitizes cell monolayers for
hydrogen peroxide-induced disruption of barrier function. 相似文献
19.
Ivano Bertini Marco Fragai Claudio Luchinat Maxime Melikian Efstratios Mylonas Niko Sarti Dmitri I. Svergun 《The Journal of biological chemistry》2009,284(19):12821-12828
The presence of extensive reciprocal conformational freedom between the
catalytic and the hemopexin-like domains of full-length matrix
metalloproteinase-1 (MMP-1) is demonstrated by NMR and small angle x-ray
scattering experiments. This finding is discussed in relation to the
essentiality of the hemopexin-like domain for the collagenolytic activity of
MMP-1. The conformational freedom experienced by the present system, having
the shortest linker between the two domains, when compared with similar
findings on MMP-12 and MMP-9 having longer and the longest linker within the
family, respectively, suggests this type of conformational freedom to be a
general property of all MMPs.Matrix metalloproteinases
(MMP)2 are
extracellular hydrolytic enzymes involved in a variety of processes including
connective tissue cleavage and remodeling
(1–3).
All 23 members of the family are able to cleave simple peptides derived from
connective tissue components such as collagen, gelatin, elastin, etc. A subset
of MMPs is able to hydrolyze more resistant polymeric substrates, such as
cross-linked elastin, and partially degraded collagen forms, such as gelatin
and type IV collagens (4).
Intact triple helical type I–III collagen is only attacked by
collagenases MMP-1, MMP-8, and MMP-13 and by MMP-2 and MMP-14
(5–12).
Although the detailed mechanism of cleavage of single chain peptides by MMP
has been largely elucidated
(13–19),
little is known about the process of hydrolysis of triple helical collagen. In
fact, triple helical collagen cannot be accommodated in the substrate-binding
groove of the catalytic site of MMPs
(9).All MMPs (but MMP-7) in their active form are constituted by a catalytic
domain (CAT) and a hemopexin-like domain (HPX)
(20–22).
The CAT domain contains two zinc ions and one to three calcium ions. One zinc
ion is at the catalytic site and is responsible for the activity, whereas the
other metal ions have structural roles. The isolated CAT domains retain full
catalytic activity toward simple peptides and single chain polymeric
substrates such as elastin, whereas hydrolysis of triple helical collagen also
requires the presence of the HPX domain
(9,
23–25).
It has been shown that the isolated CAT domain regains a small fraction of the
activity of the full-length (FL) protein when high amounts of either
inactivated full-length proteins or isolated HPX domains are added to the
assay solution (9). Finally, it
has been shown that the presence of the HPX domain alone alters the CD
spectrum of triple helical collagen in a way that suggests its partial
unwinding (26,
27). It is tempting to
speculate that full-length collagenases attack collagen by first locally
unwinding the triple helical structure with the help of the HPX domain and
then cleaving the resulting, exposed, single filaments
(9,
28).Until 2007, three-dimensional structures of full-length MMPs had been
reported only for collagenase MMP-1
(29–31)
and gelatinase MMP-2 (32). The
structures of the two proteins are very similar and show a compact arrangement
of the two domains, which are connected by a short linker (14 and 20 amino
acids, respectively). It is difficult to envisage that rigid and compact
molecules of this type can interact with triple helical collagen in a way that
can lead to first unwinding and then cleavage of individual filaments. It has
been recently suggested that such concerted action could occur much more
easily if the two domains could enjoy at least a partial conformational
independence (9). Slight
differences in the reciprocal orientation of the CAT and HPX domains of MMP-1
in the presence (29) and
absence (30,
31) of the prodomain were
indeed taken as a hint that the two domains could experience relative mobility
(29).Two recent solution studies have shown that conformational independence is
indeed occurring in gelatinase MMP-9
(33) and elastase MMP-12
(34), whereas the x-ray
structure of the latter (34)
is only slightly less compact than those of MMP-1
(29–31)
and MMP-2 (32). Among MMPs,
MMP-9 features an exceptionally long linker (68 amino acid)
(33,
35), which in fact constitutes
a small domain by itself (the O-glycosylated domain)
(33), and therefore, this
inspiring observation can hardly be taken as evidence that conformational
freedom is a general characteristic of the two-domain MMPs. MMP-12 features a
much more normal 16-amino acid linker, thereby making more probable a general
functional role for this conformational freedom
(34). However, both MMP-9 and
MMP-12 retain their full catalytic activity against their substrates even when
deprived of the HPX domain (9).
Therefore, the question remains of whether conformational freedom is also a
required characteristic for those MMPs that are only active as full-length
proteins, i.e. collagenases. Interestingly, the three collagenases
(MMP-1, MMP-8, and MMP-13) have the shortest linker (14 amino acids) among all
MMPs. Demonstrating or negating the presence of conformational freedom in one
of these collagenases would therefore constitute a significant step forward to
formulate mechanistic hypotheses on their collagenolytic activity.Our recent studies on MMP-12 in solution
(34) have shown that a
combination of NMR relaxation studies and small angle x-ray scattering (SAXS)
is enough to show the presence and the extent of the relative conformational
freedom of the two domains of MMPs. Here we apply the same strategy to
full-length MMP-1 and show that sizable conformational freedom is indeed
experienced even by this prototypical collagenase, although somewhat less
pronounced than that observed for MMP-12. 相似文献
20.
Kuen-Feng Chen Pei-Yen Yeh Chiun Hsu Chih-Hung Hsu Yen-Shen Lu Hsing-Pang Hsieh Pei-Jer Chen Ann-Lii Cheng 《The Journal of biological chemistry》2009,284(17):11121-11133
Hepatocellular carcinoma (HCC) is one of the most common and aggressive
human malignancies. Recombinant tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) is a promising anti-tumor agent. However,
many HCC cells show resistance to TRAIL-induced apoptosis. In this study, we
showed that bortezomib, a proteasome inhibitor, overcame TRAIL resistance in
HCC cells, including Huh-7, Hep3B, and Sk-Hep1. The combination of bortezomib
and TRAIL restored the sensitivity of HCC cells to TRAIL-induced apoptosis.
Comparing the molecular change in HCC cells treated with these agents, we
found that down-regulation of phospho-Akt (P-Akt) played a key role in
mediating TRAIL sensitization of bortezomib. The first evidence was that
bortezomib down-regulated P-Akt in a dose- and time-dependent manner in
TRAIL-treated HCC cells. Second, , a PI3K inhibitor, also sensitized
resistant HCC cells to TRAIL-induced apoptosis. Third, knocking down Akt1 by
small interference RNA also enhanced TRAIL-induced apoptosis in Huh-7 cells.
Finally, ectopic expression of mutant Akt (constitutive active) in HCC cells
abolished TRAIL sensitization effect of bortezomib. Moreover, okadaic acid, a
protein phosphatase 2A (PP2A) inhibitor, reversed down-regulation of P-Akt in
bortezomib-treated cells, and PP2A knockdown by small interference RNA also
reduced apoptosis induced by the combination of TRAIL and bortezomib,
indicating that PP2A may be important in mediating the effect of bortezomib on
TRAIL sensitization. Together, bortezomib overcame TRAIL resistance at
clinically achievable concentrations in hepatocellular carcinoma cells, and
this effect is mediated at least partly via inhibition of the PI3K/Akt
pathway.Hepatocellular carcinoma
(HCC) LY2940022 is currently
the fifth most common solid tumor worldwide and the fourth leading cause of
cancer-related death. To date, surgery is still the only curative treatment
but is only feasible in a small portion of patients
(1). Drug treatment is the
major therapy for patients with advanced stage disease. Unfortunately, the
response rate to traditional chemotherapy for HCC patients is unsatisfactory
(1). Novel pharmacological
therapy is urgently needed for patients with advanced HCC. In this regard, the
approval of sorafenib might open a new era of molecularly targeted therapy in
the treatment of HCC patients.Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL), a
type II transmembrane protein and a member of the TNF family, is a promising
anti-tumor agent under clinical investigation
(2). TRAIL functions by
engaging its receptors expressed on the surface of target cells. Five
receptors specific for TRAIL have been identified, including DR4/TRAIL-R1,
DR5/TRAIL-R2, DcR1, DcR2, and osteoprotegerin. Among TRAIL receptors, only DR4
and DR5 contain an effective death domain that is essential to formation of
death-inducing signaling complex (DISC), a critical step for TRAIL-induced
apoptosis. Notably, the trimerization of the death domains recruits an adaptor
molecule, Fas-associated protein with death domain (FADD), which subsequently
recruits and activates caspase-8. In type I cells, activation of caspase-8 is
sufficient to activate caspase-3 to induce apoptosis; however, in another type
of cells (type II), the intrinsic mitochondrial pathway is essential for
apoptosis characterized by cleavage of Bid and release of cytochrome
c from mitochondria, which subsequently activates caspase-9 and
caspase-3 (3).Although TRAIL induces apoptosis in malignant cells but sparing normal
cells, some tumor cells are resistant to TRAIL-induced apoptosis. Mechanisms
responsible for the resistance include receptors and intracellular resistance.
Although the cell surface expression of DR4 or DR5 is absolutely required for
TRAIL-induced apoptosis, tumor cells expressing these death receptors are not
always sensitive to TRAIL due to intracellular mechanisms. For example, the
cellular FLICE-inhibitory protein (c-FLIP), a homologue to caspase-8 but
without protease activity, has been linked to TRAIL resistance in several
studies (4,
5). In addition, inactivation
of Bax, a proapoptotic Bcl-2 family protein, resulted in resistance to TRAIL
in MMR-deficient tumors (6,
7), and reintroduction of Bax
into Bax-deficient cells restored TRAIL sensitivity
(8), indicating that the Bcl-2
family plays a critical role in intracellular mechanisms for resistance of
TRAIL.Bortezomib, a proteasome inhibitor approved clinically for multiple myeloma
and mantle cell lymphoma, has been investigated intensively for many types of
cancer (9). Accumulating
studies indicate that the combination of bortezomib and TRAIL overcomes the
resistance to TRAIL in various types of cancer, including acute myeloid
leukemia (4), lymphoma
(10–13),
prostate
(14–17),
colon (15,
18,
19), bladder
(14,
16), renal cell carcinoma
(20), thyroid
(21), ovary
(22), non-small cell lung
(23,
24), sarcoma
(25), and HCC
(26,
27). Molecular targets
responsible for the sensitizing effect of bortezomib on TRAIL-induced cell
death include DR4 (14,
27), DR5
(14,
20,
22–23,
28), c-FLIP
(4,
11,
21–23,
29), NF-κB
(12,
24,
30), p21
(16,
21,
25), and p27
(25). In addition, Bcl-2
family also plays a role in the combinational effect of bortezomib and TRAIL,
including Bcl-2 (10,
21), Bax
(13,
22), Bak
(27), Bcl-xL
(21), Bik
(18), and Bim
(15).Recently, we have reported that Akt signaling is a major molecular
determinant in bortezomib-induced apoptosis in HCC cells
(31). In this study, we
demonstrated that bortezomib overcame TRAIL resistance in HCC cells through
inhibition of the PI3K/Akt pathway. 相似文献